Thrombin Receptor Antibody - #AF0263

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(7)   (12)  
产品: Thrombin Receptor 抗体
货号: AF0263
描述: Rabbit polyclonal antibody to Thrombin Receptor
应用: WB IHC IF/ICC
文献验证: WB, IHC, IF/ICC
反应: Human, Mouse, Rat
分子量: 48kDa; 47kD(Calculated).
蛋白号: P25116
RRID: AB_2833437

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:3000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Thrombin Receptor Antibody detects endogenous levels of total Thrombin Receptor.
RRID:
AB_2833437
引用格式: Affinity Biosciences Cat# AF0263, RRID:AB_2833437.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

CF2R; Coagulation factor II (thrombin) receptor; Coagulation factor II receptor; F2R; HTR; PAR 1; PAR-1; PAR1; PAR1_HUMAN; Protease activated receptor 1; Proteinase activated receptor 1; Proteinase-activated receptor 1; Thrombin receptor; TR;

抗原和靶标

免疫原:
Uniprot:

P25116(PAR1_HUMAN) >>Visit HPA database.

基因/基因ID:
F2R(2149)
表达:
P25116 PAR1_HUMAN:

Platelets and vascular endothelial cells.

描述:
PAR1 a G-protein coupled high-affinity receptor for activated thrombin or trypsin. Coupled to G proteins that stimulate phosphoinositide hydrolysis. Coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelet activation and in vascular development.
序列:
MGPRRLLLVAACFSLCGPLLSARTRARRPESKATNATLDPRSFLLRNPNDKYEPFWEDEEKNESGLTEYRLVSINKSSPLQKQLPAFISEDASGYLTSSWLTLFVPSVYTGVFVVSLPLNIMAIVVFILKMKVKKPAVVYMLHLATADVLFVSVLPFKISYYFSGSDWQFGSELCRFVTAAFYCNMYASILLMTVISIDRFLAVVYPMQSLSWRTLGRASFTCLAIWALAIAGVVPLLLKEQTIQVPGLNITTCHDVLNETLLEGYYAYYFSAFSAVFFFVPLIISTVCYVSIIRCLSSSAVANRSKKSRALFLSAAVFCIFIICFGPTNVLLIAHYSFLSHTSTTEAAYFAYLLCVCVSSISCCIDPLIYYYASSECQRYVYSILCCKESSDPSSYNSSGQLMASKMDTCSSNLNNSIYKKLLT

研究背景

功能:

High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation and in vascular development.

翻译修饰:

A proteolytic cleavage generates a new N-terminus that functions as a tethered ligand.

Phosphorylated in the C-terminal tail; probably mediating desensitization prior to the uncoupling and internalization of the receptor.

细胞定位:

Cell membrane>Multi-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Platelets and vascular endothelial cells.

蛋白家族:

The cleaved signal peptide may not be degraded and may function as an intracellular angiogenesis inhibitor peptide known as parstatin.

Belongs to the G-protein coupled receptor 1 family.

研究领域

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Calcium signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Neuroactive ligand-receptor interaction.

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Organismal Systems > Immune system > Complement and coagulation cascades.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

文献引用

1). Thrombin receptor activating peptide-6 decreases acute graft-versus-host disease through activating GPR15. Leukemia, 2024 (PubMed: 38459169) [IF=12.8]
2). Gut microbiome and serum short-chain fatty acids are associated with responses to chemo- or targeted therapies in Chinese patients with lung cancer. Frontiers in microbiology, 2023 (PubMed: 37564290) [IF=5.2]

Application: IF/ICC    Species: human    Sample: LC cells

Figure 5. Isobutyric acid regulated G protein-coupled receptor (GPCR) expression and histone acetyltransferase (HAT) activity. For the expression of GPCRs, the results of RT-qPCR (A), Western blot (B), and immunocytochemical staining (C) showed that GPR41, GPR43, and GPRC5A expressions were significantly higher, while PAR1 expression was significantly lower in isobutyric acid treatment group (1.85 mM) than the control groups (control and NC). Immunofluorescence staining (D) identified the expression location of GPCRs. For the expression of acetyl-histones and histones, the results of Western blot (E) and immunocytochemical staining (F) showed that acetyl-histone H3 and H4 expressions were significantly higher in the isobutyric acid treatment group (1.85 mM) than the control groups (control and NC), whereas Western blot results showed that there was no significant difference of the expression of histone H3 and H4 between isobutyric acid treatment group and the control groups. Immunofluorescence staining (G) identified the expression location of acetyl-histone H3 and H4. HAT activity assay (H) results showed that HAT activity was increased in the isobutyric acid treatment group (1.85mM) than in the control groups (control and NC). P-values were calculated using Student's t-tests. ns: no significance; *p < 0.05; **p < 0.01; ***p < 0.001. All experiments were repeated three times. NC, negative control (0mM).

Application: IHC    Species: human    Sample: LC cells

Figure 5. Isobutyric acid regulated G protein-coupled receptor (GPCR) expression and histone acetyltransferase (HAT) activity. For the expression of GPCRs, the results of RT-qPCR (A), Western blot (B), and immunocytochemical staining (C) showed that GPR41, GPR43, and GPRC5A expressions were significantly higher, while PAR1 expression was significantly lower in isobutyric acid treatment group (1.85 mM) than the control groups (control and NC). Immunofluorescence staining (D) identified the expression location of GPCRs. For the expression of acetyl-histones and histones, the results of Western blot (E) and immunocytochemical staining (F) showed that acetyl-histone H3 and H4 expressions were significantly higher in the isobutyric acid treatment group (1.85 mM) than the control groups (control and NC), whereas Western blot results showed that there was no significant difference of the expression of histone H3 and H4 between isobutyric acid treatment group and the control groups. Immunofluorescence staining (G) identified the expression location of acetyl-histone H3 and H4. HAT activity assay (H) results showed that HAT activity was increased in the isobutyric acid treatment group (1.85mM) than in the control groups (control and NC). P-values were calculated using Student's t-tests. ns: no significance; *p < 0.05; **p < 0.01; ***p < 0.001. All experiments were repeated three times. NC, negative control (0mM).

Application: WB    Species: human    Sample: LC cells

Figure 5. Isobutyric acid regulated G protein-coupled receptor (GPCR) expression and histone acetyltransferase (HAT) activity. For the expression of GPCRs, the results of RT-qPCR (A), Western blot (B), and immunocytochemical staining (C) showed that GPR41, GPR43, and GPRC5A expressions were significantly higher, while PAR1 expression was significantly lower in isobutyric acid treatment group (1.85 mM) than the control groups (control and NC). Immunofluorescence staining (D) identified the expression location of GPCRs. For the expression of acetyl-histones and histones, the results of Western blot (E) and immunocytochemical staining (F) showed that acetyl-histone H3 and H4 expressions were significantly higher in the isobutyric acid treatment group (1.85 mM) than the control groups (control and NC), whereas Western blot results showed that there was no significant difference of the expression of histone H3 and H4 between isobutyric acid treatment group and the control groups. Immunofluorescence staining (G) identified the expression location of acetyl-histone H3 and H4. HAT activity assay (H) results showed that HAT activity was increased in the isobutyric acid treatment group (1.85mM) than in the control groups (control and NC). P-values were calculated using Student's t-tests. ns: no significance; *p < 0.05; **p < 0.01; ***p < 0.001. All experiments were repeated three times. NC, negative control (0mM).
3). TREM2 improves coagulopathy and lung inflammation in sepsis through the AKT-mTOR pathway. International immunopharmacology, 2025 (PubMed: 39970715) [IF=4.8]
4). Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia. MOLECULAR HUMAN REPRODUCTION, 2018 (PubMed: 29325127) [IF=3.6]
5). pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1. BREAST CANCER RESEARCH AND TREATMENT, 2020 (PubMed: 32034579) [IF=3.0]

Application: IF/ICC    Species: Human    Sample: MDA-MB-231 and MCF-10A cells

Fig. 1 PAR1 expression was positive in MDA-MB-231 cells, and PAR1 expression was negative in MCF-10A cells (400 ×)
6). Expression and clinical implications of PARs in the stenotic tissue of ureteropelvic junction obstruction. Frontiers in pediatrics, 2023 (PubMed: 38161438) [IF=2.1]

Application: IF/ICC    Species: human    Sample:

Figure 1. Immunofluorescence double staining was conducted on PAR1 with various types of SIP syncytium. (A) Immunofluorescence double staining of PAR1 (red) and c-kit (green) in UPJ control; (B) immunofluorescence double staining of PAR1 (red) and c-kit (green) in UPJO; (C) immunofluorescence double staining of PAR1 (red) and phalloidin (green) in UPJ control; (D) immunofluorescence double staining of PAR1 (red) and phalloidin (green) in UPJO; (E) immunofluorescence double staining of PAR1 (red) and PDGFRα (green) in UPJ control; (F) immunofluorescence double staining of PAR1 (red) and PDGFRα (green) in UPJO. The blue areas in all images represent DAPI-labelled nuclei. Nuclei were counterstained with DAPI (blue) in all panels. Bar = 50 μm in all panels.
7). Doxycycline directly targets PAR1 to suppress tumor progression. Oncotarget, 2017 (PubMed: 28187433)

Application: IF/ICC    Species: human    Sample:

(G) Confocal immunofluorescence imaging was performed to visualize PAR1 and doxycycline. PAR1 and doxycycline co-localize, with a Pearson’s correlation coeffcient of 0.944 and a Mander’s overlap of 0.964.

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.